TOP¡ä°å¶É¤Î¤´¾Ò²ð¡ä¶ÈÀÓ¾Ò²ð¡Ê2008¡Á2009ǯ¡Ë
¶ÈÀÓ¾Ò²ð
2009ǯ
¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð
- Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamahita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A ; Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.
Am J Med Genet B Neuropsychiatr Genet ; 150B(1)115-123
- Kato M, Okugawa G, Wakeno M, Takekita Y, Nonen S, Tetsuo S, Nishida K, Azuma J, Kinoshita T, Serretti A ; Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. European neuropsychopharmacology19(10)718-25
- Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, Colombo C, Serritti A ; 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients ; Psychiatric Research167(1-2)97-105
- Kinoshita T ; Epigenetics in Psychiatry. Neuropsychobiology60(1)1
- Okugawa G, Kato M, Wakeno M, Koh J, Morikawa M, Matsumoto N, Shinosaki K, Yoneda H, Kishimoto T, Kinoshita T ; Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai psychiatric multicenter study. Psychiatry and clinical neurosciences 63(3)322-328
- Tsutsumi A, Kanazawa T, Kikuyama H, Okugawa G, Uenishi H, Miyamoto T, Matsumoto N, Koh J, Shinosaki K, Kishimoto T, Yoneda H, Kinoshita T ; Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone.Psychiatry Investigation 6(3)222-225
- Lawyer G, Nesvag R, Varnas K, Okugawa G, Aqartz I ; Grey and White Matter Propotional Relationships in the Cerebellar Vermis Altered in Schizophrenia.Cerebellum 8(1)52-60,2009
- Morishita S, Kinoshita T ; Gender differences in response to antidepressants.Current topics in pharmacology 13(2)51-64
- ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤Ë̸µ ·ò¡¤ Æþß· ÁÌÚ²¼Íøɧ ; ½éÏ·´ü¤Ë¤ß¤é¤ì¤ëÍÞ¤¦¤Ä¾É¾õ¤ËÂФ·¤Æ¥ê¥Á¥¦¥à¤¬ÁÕ¸ú¤·¤¿2¾ÉÎã.Bipolar disorder 7:13-19
- ÌÚ²¼Íøɧ ; ¿·µ¬¹³¤¦¤ÄÌômirtazapine¤Î¤¦¤ÄɵڤӤ¦¤Ä¾õÂ֤δµ¼Ô¤òÂоݤȤ·¤¿¥×¥é¥»¥ÜÂоÈÆó½ÅÌÕ¸¡Èæ³Ó»î¸³.Î×¾²Àº¿ÀÌôÍý12(2):289-306
- ÌÚ²¼Íøɧ ; ¿·µ¬¤¦¤ÄÌômirtazapine¤Î¤¦¤ÄɵڤӤ¦¤Ä¾õÂ֤δµ¼Ô¤òÂоݤȤ·¤¿Ä¹´üÅêÍ¿»î¸³.Î×¾²Àº¿ÀÌôÍý12(3):503-520
- À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë¡¤ µÈÅľ﹧¡¤Æþß·Á¿¹ÅļÓÀ顤°ëë½ÓÌÀ¡¤ ÌÚ²¼Íøɧ ; FTD(frontotemporal dementia)´µ¼Ô¤Î¼þÇÈ¿ô²òÀϤòÍѤ¤¤¿¸¦µæ.ÆüËÜÌôʪǾÇȳزñ»¨»ï10(1):63-66
- óîÆ£¹¬»Ò ; ¶¯Ç÷À¾ã³²¤Ë¤ª¤±¤ë¿·¤·¤¤Ç¾²èÁü¸¦µæ(³È»¶¥Æ¥ó¥½¥ë²èÁü²òÀϤˤè¤ëÎ×¾²½Å¾ÉÅÙȽÄê¤Î²ÄǽÀ¤Ë¤Ä¤¤¤Æ). ´ØÀ¾°å²ÊÂç³Ø»¨»ï61(2):212-21
- ÅĶᰡÍö¡¤°¤Éô¾°¡¤ºä°æ»ÖÈÁ¡¤ ʬÌîÀµµ®¡¤¾åÌîÀéÊ桤µÈ¼¶©»Ë¡¤ÌÚ²¼Íøɧ ; ¥¨¥È¥µ¥¯¥·¥ß¥É¤Ë¤è¤êǾÇȤζ¯À©Àµ¾ï²½¤òÍ褿¤·åÈÌÛ¾õÂÖ¤òÄ褷¤¿°ìÎã.Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï20(1)3-8
- ¾åÌîÀéÊ桤ÌÚ²¼Íøɧ¡¤ »³Ëܹ¬ÎÉ ; Àº¿À²Ê°å¤¬½Ð²ñ¤¦È¯Ã£¾ã³²¼Ô¤ÎÎ×¾²ÅªÌäÂêÅÀ¡½¤È¤¯¤Ë¹ÈÆÀȯã¾ã³²¤òÃæ¿´¤Ë.ÆüËÜÀº¿À²Êɱ¡¶¨²ñ»¨»ï28(8)646-652
- µÈ¼¶©»Ë¡¤°ëë½ÓÌÀ¡¤Æþß· ÁÀ¾ÅÄ·½°ìϺ¡¤»³ÅÄ·½Â¤¡¤ ¿¹ÅļÓÀ顤 ÖÖË̲µ±¡¤Ë̱ºÍ´°ì¡¤¿Ûˬ°´¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ¹³Àº¿ÀÉÂÌôñ²óÅêÍ¿¤¬·ò¾ï¼Ô¤ÎǾÅžì¤ËµÚ¤Ü¤¹±Æ¶Á Êñ³çŪ»Øɸ¤òÍѤ¤¤Æ.ÆüËÜÌôʪǾÇȳزñ»¨»ï 10(1)43-48
- µÈ¼¶©»Ë¡¤ã·Æ£¹¬»Ò¡¤±ä¸¶·òÆó¡¤ °ëë½ÓÌÀ¡¤µÆÃÓ ½¼¡¤ ±üÀî ³Ø¡¤Æþß· ÁÀ¾ÅÄ·½°ìϺ¡¤¿¹ÅļÓÀ顤Ë̱ºÍ´°ì¡¤Koenig Thomas¡¤ÌÚ²¼Íøɧ ; ǾÇÈ¡¦¶ÚÅÅ¿Þ¤ÎÎ×¾² ¶¯Ç÷À¾ã³²¤Î¶õ´ÖŪǾµ¡Ç½¸¦µæ ¾É¾õͶȯ¤Ë¤è¤ëÊѲ½.Î×¾²Ç¾ÇÈ51(9)560-567
- À¾Â¼±ÉÄŻҡ¤ »°°æ¹À¡¤Ã«Ëü´î»Ò¡¤¹âÅĤ¢¤ä¡¤ÎëÌÚ½ÓÌÀ¡¤ÌÚ²¼Íøɧ¡¤ÌøÀ¸Î´»ë ; ÁжËÀ¾ã³²¤Î²ÃÎÅÃæ¤ËÀ¸¤¸¤¿ÃÙȯÀ¥¸¥¹¥È¥Ë¥¢¤ËÂФ¹¤ë謁£ÎÅ.´ØÀ¾°åÎÅÂç³ØµªÍ×3:115-120
- ¾åÅľȻҡ¤»°Âð¿¿Íý¡¤À¾»³ÍøÀµ¡¤ÅĶᰡÍö¡¤ ¹Ó°æͳÈþ»Ò ; Íײð¸î¹âÎð¼Ô¤Î©»Ò¤Ë¤è¤ëµÔÂÔ¤ÎÍ×°ø¤È¿ȯ¤ÎÇØ·Ê¡¥¸üÀ¸¤Î»Øɸ55(6):19-26
- »°ÂðâÃÍý¡¤Anne Rock¡¤ÅĶᰡÍö¡¤ÊÝÄÅ¿¿°ìϺ¡¤¿ÎÌÚÌ¡¤Ê¿ÌÚ¹¨»ù¡¤ À¾»³ÍøÀµ ; ¥ª¡¼¥¹¥È¥é¥ê¥¢¤ÈÆüËܤιâÎð¼Ô²ð¸î»ÜÀߤˤª¤±¤ë¥±¥¢¤Ë¤Ä¤¤¤Æ¤Î¸¦µæ.¥ª¡¼¥¹¥È¥é¥ê¥¢¸¦µæ22:73-75
Ãø½ñ
- ÌÚ²¼Íøɧ¡¤À¾ÅÄ·½°ìϺ¡¤µÈ¼¶©»Ë ; µ¿ÇÃǤò¤Ä¤±¤ë¤¿¤á¤Ë F.¸¡ºº 1.¿À·ÐÀ¸Íý¸¡ºº. Àº¿À²ÊÀìÌç°å¤Î¤¿¤á¤Î¥×¥é¥¯¥Æ¥£¥«¥ëÀº¿À°å³Ø ; 177-186 Ã滳½ÐÈÇ
- Nishida K, Yoshimura M, Suwa A, Kitaura Y, Kono S, Isotani T, Kinoshita T ; A Case Report:The Change of EEG Findings in General Paresis before and after Penicillin-G Treatment.Brain Topography and multimodal imaging ; 253-255µþÅÔÂç³Ø³Ø½Ñ½ÐÈÇ
- ¿ùËÜãºÈ ; ¤¦¤ÄÌôÃæÆÇ(»°´Ä·Ï¡¢»Í´Ä·Ï)¡¢Ãº»À¥ê¥Á¥¦¥àÃæÆÇ.º£Æü¤Î¼£ÎÅ»Ø¿Ë 2009ǯÈÇ(Vol.51) ; 115-116 °å³Ø½ñ±¡
2008ǯ
¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð
- Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y,Takekita Y, Mandelli L, Azuma J, Kinoshita T ; ABCB1MDR1gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.Prog Neuropsychopharmacol Biol Psychiatry 32(2)398-404
- Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamahita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A ; Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.
Am J Med Genet B Neuropsychiatr Genet.150B(1)115-123
- Kato M, Wakeno M, Okugawa G, Fukuda T, Takekita Y, Hosoi Y, Azuma J, Kinoshita T, Serretti A2008Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
Prog Neuropsychopharmacol Biol Psychiatry32(4)1041-1044
- Morishita S, Kinoshita T ; Predictors of response to sertraline in patients
with major depression. Hum.Psychopharmacol Clin Exp 23:647-651
- Saito Y, Nobuhara K, Okugawa G, Takase K, Sugimoto T, Horiuchi M, Ueno C, Maehara M, Omura N, Kurokawa H, Ikeda K, Tanigawa N, Sawada S, Kinoshita T ; Corpus Callosum in Patients with Obsessive-Compulsive Disorder: Diffusion-Tensor Imaging Study. Radiology246(2)536-542.
- Serretti A, Kato M ; The serotonin transporter gene and effectiveness of SSRIs.
Expert Rev Neurother 8(1111-120
- Serretti A, Kato M, Kennedy JL ; Pharmacogenetic studies in depression: a proposal for methodologic guidelines.Pharmacogenomics J 8(2)90-100
- Sugimoto T, Tanigawa N, Ikeda K, Ohmura N, Maehara M, Kariya S, Kojima H, Komemushi A, Ha-Kawa SK, Saito.Y, Tajika A, Kinoshita T, Sawada S ; Diffusion-Weighted Imaging for Predicting New Compression Fractures Following Percutaneous Vertebroplasty. Acta Radiologica 49(4)419-426.
- Tani M, Suzuki T, Takada A, Yagyu T, Kinoshita T ; The acupuncture treatment of severe
axial dystonia The Journal of Chinese Medicine 87: 5-8
- Wakeno M, Kato M, Okugawa G, Fukuda T, Hosoi Y, Takekita Y, Yamashita M, Nonen S, Azuma J, Kinoshita T ; The Alpha 2A-Adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. J Clin Psychopharmacol 28(5)518-524
- ÊÒ¾åůÌ顤¿¥ÅÄ͵¹Ô¡¤Ë̸µ ·ò¡¤»³ÅÄ·½Â¤¡¤ÌÚ²¼Íøɧ ; ÁжËÀÀ®Ê¬¤ËÃíÌܤ¹¤ë¤³¤È¤Ë¤è¤êÁжËÀ¾ã³²¤Ë¿ÇÃǤòÊѹ¹¤·²þÁ±¤¬¤ß¤é¤ì¤¿µ¤Ê¬¾ã³²¤Î12Îã¤Ë¤Ä¤¤¤Æ¤Î¹Í»¡¡¥Bipolar Disorder 6: 32-36
- ÌÚ²¼Íøɧ ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëblonanserin¤ÎĹ´üÅêÍ¿»î¸³ ¿»ÜÀ߶¦Æ±¥ª¡¼¥×¥ó»î¸³¡¥Î×¾²Àº¿ÀÌôÍý11(1)135-153
- ¿¹ÅļÓÀ顤¾åÌîÀéÊ桤¹âÀ¥¾¡¶µ¡¤Æî Ãҵס¤Ê¬ÌîÀµµ®¡¤ÖÖË̲µ±¡¢Æþß· Á±üÀî ³Ø¡¤ÌÚ²¼Íøɧ ; ǾÇÈ°Û¾ï¤òȼ¤Ã¤¿¼ãǯ¼þ´üÀº¿Àɤΰì¾ÉÎã¡¥Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï181)11-15
- Ë̸µ ·ò¡¤¹âÀ¥¾¡¶µ¡¤»³ÅÄ·½Â¤¡¤ÌÚ²¼Íøɧ ; ¿ÇÃǤ¬º¤Æñ¤Ç¤¢¤Ã¤¿Ê£»¨Éôʬȯºî¤Î£±¾ÉÎã¡¥Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï19(1)11-16
- ÎëÌÚÈþº´ ; Âç³Øɱ¡¤Ë¤ª¤±¤ëÀº¿ÀÊÝ·òÊ¡»ã»Î¤ÎÌò³ä.ÆüËÜÀº¿À²Êɱ¡¶¨²ñ»¨»ï28(9)738-743
- ¿ùËÜãºÈ¡¤´äÀ¥Àµ¸²¡¤µÜºê½¨¹Ô¡¤Æ£¸¶¹°²Â¡¤ÌÚ²¼Íøɧ¡¤ÃæëÔèÃË ; 2¥ö·î´Ö¥Õ¥©¥í¡¼¥¢¥Ã¥×¤·¤¿°ì»À²½ÃæÆǽ¸ÃÄȯÀ¸»öÎã¤ÎÊó¹ð¡¥»º¶È°å¥¸¥ã¡¼¥Ê¥ë31(1)18-22
- ÖÖË̲µ±¡¤µÈÅľ﹧¡¤À¾ÅÄ·½°ìϺ¡¤²Ï ÁêµÈ¡¤ºä°æ»ÖÈÁ¡¤Ê¬ÌîÀµµ®¡¤²ÃÆ£Àµ¼ù¡¤±üÀî ³Ø¡¤ÌÚ²¼Íøɧ ; ParoxetineÅêÍ¿¤Ë¤è¤êÁ°Æ¬Íվɾõ¤Î²þÁ±¤ò¤ß¤¿Á°Æ¬Â¦Æ¬ÊýǧÃξÉ(frontotemporal dementia)¤Î£±Îã¡¥Àº¿À²Ê13(2)165-172
- ÎëÌÚÊþ»Ò ; ¤¢¤«¤é¤µ¤Þ¤Ê¥¨¥Ç¥£¥×¥¹´ê˾¤ò¤á¤°¤ë¾ÉÎã¡¥Àº¿ÀʬÀϸ¦µæ52(1)84-89
- ÎëÌÚ½ÓÌÀ¡¤Ã«Ëü´î»Ò¡¤¼ã»³°éϺ¡¤µÈÅĽ¡Ê¿¡¤ÌÚ²¼Íøɧ¡¤ÌøÀ¸Î´»ë¡¢¹âÅĤ¢¤ä¡¤°æ¾åÇ ; ¥¸¥¹¥È¥Ë¥¢´µ¼Ô¤ËÂФ¹¤ë謁£ÎŸú²Ì¤Ë´Ø¤¹¤ë¸¡Æ¤ ¡Ý¶ÚÅÅ¿Þ³ØŪɾ²Á¤È¿´ÍýŪ¦Ì̤«¤é¤Îɾ²Á¡Ý¡¥´ØÀ¾°åÎÅÂç³ØµªÍ×£²:110-117
- µÈÌî¿¿µª¡¤ÃæÊ¿¶Ç»Ò¡¤¿¥ÅÄ͵¹Ô¡¤ÎëÌÚÊþ»Ò¡¤ÅĶá ʸ¡¤ÍÌڱʻҡ¤ÌÚ²¼Íøɧ ; ¥í¡¼¥ë¥·¥ã¥Ã¥Ï¥Æ¥¹¥È¤«¤é¤ß¤¿ÀƱ°ìÀ¾ã³²¡¥¿´ÍýÎ×¾²³Ø¸¦26(1)13-23
- ÃæÊ¿¶Ç»Ò¡¤µÈÌî¿¿µª¡¤¿¥ÅÄ͵¹Ô¡¤ÎëÌÚÊþ»Ò¡¤ÅĶá ʸ¡¤ÍÌڱʻҡ¤ÌÚ²¼Íøɧ ; ÀƱ°ìÀ¾ã³²¤Ë¤ª¤±¤ë¥í¡¼¥ë¥·¥ã¥Ã¥Ï¥Æ¥¹¥È¤ÎÆÃħ¡ÝMTF¤ÈFTM¤ÎÈæ³Ó¤«¤é¡Ý¡¥¥í¡¼¥ë¥·¥ã¥Ã¥ÏË¡¸¦µæ12(1)1-9
- Ê¡ÅĹä»Ë¡¤»³²¼·Ã¼Â¡¤Åì ½ã°ì¡¤²ÃÆ£Àµ¼ù ; ¹³¤¦¤ÄÌô¤Î¼£ÎŸú²Ì¤Ë±Æ¶Á¤¹¤ëʬ»Ò¤Ë´Ø¤¹¤ë¥²¥Î¥àÌôÍý³ØŪ¸¦µæ¡ÝǾÆðÛŪtryptophan hydroxylase2¡Ý£²°äÅÁ»Ò·¿¤òÃæ¿´¤Ë¡¥Î×¾²ÌôÍý¤Î¿ÊÊâ29:155-167
- ²£¾®Ï©Èþµ®»Ò¡¤»°ÆÑ°¡ÈÞ¡¤Ä¹Èø´î°ìϺ¡¤ÌÚ²¼Íøɧ ; ¥ê¥¹¥Ñ¥À¡¼¥ë¤«¤é¥¸¥§¥Í¥ê¥Ã¥¯¤Î¥ê¥¹¥Ú¥ê¥É¥ó¤ËÊѹ¹¤·Àº¿À¾É¾õ¤¬°²½¤·¤¿Åý¹ç¼ºÄ´¾É¤Î£±Îã¡¥ ¿·Ìô¤ÈÎ×¾²57(3):346-366
- ¼ºê¸÷Ë®¡¤¾®»³ »Ê¡¤°ËЮ²í¿Ã¡¤Àж¿²¬½ã¡¤¾åÅç¹ñÍø¡¤È¬ÌÚ¹äÊ¿¡¤ÈøºêµªÉס¤Ê¡µï¸²Æó¡¤ÉðÅIJí½Ó¡¤ÊÆÅÄ ÇÌÚ²¼Íøɧ¡¤¿ÀÄí½Å¿®¡¤Á°Åĵ×ͺ Perospirone¤Î½éȯÅý¹ç¼ºÄ´¾É¤ËÂФ¹¤ë»ÔÈθåÄ´ºº ¡Ý͸úÀ¤È°ÂÁ´À¤Î¸¡Æ¤¡½¡¥Î×¾²Àº¿ÀÌôÍý11(8)1531-1550
Ãø½ñ
- ÌÚ²¼Íøɧ ; ¤¦¤Äɤò»ý¤Ä¿Í¤Î¿´¤ÎÍÍÁê¡¥¿·¸½Âå¤Î¥¨¥¹¥×¥êNo.487 ³°ÍèÀº¿À°åÎÅ¥·¥ê¡¼¥º¶ ¸½Âå¤Î¤³¤³¤í¤ÎÉ pp47-56 »êʸƲ
- µÈÌî¿¿µª¡¤ÃæÊ¿¶Ç»Ò ; ¿´ÍýÎ×¾²¤ÈÅê±ÆË¡ ¥¸¥§¥ó¥À¡¼ÌäÂê¤ÈÅê±ÆË¡¡¥ ¸½Âå¤Î¥¨¥¹¥×¥ê(Ê̺ý10·î)236-244